Last updated: May 04, 2026

Application No. 18/287,255

Dimeric Antigen Receptors (DARs) that Bind GD2

Non-Final OA

Filed

Oct 17, 2023

Priority

Apr 23, 2021 — provisional 63/179,147 +2 more

Examiner

JUEDES, AMY E

Art Unit

1644

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Sorrento Therapeutics Inc.

OA Round

1 (Non-Final)

This examiner grants 45% of cases after interview

— +40.5% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 898 resolved cases, 2023–2026

Examiner Intelligence

JUEDES, AMY E View full profile →

Grants 45% of resolved cases

Career Allowance Rate

401 granted / 898 resolved

-15.3% vs TC avg

Strong +40% interview lift

Without

With

+40.5%

Interview Lift

resolved cases with interview

Typical timeline

3y 9m

Avg Prosecution

80 currently pending

Career history

978

Total Applications

across all art units

Statute-Specific Performance

§101

0.8%

-39.2% vs TC avg

§103

35.7%

-4.3% vs TC avg

§102

11.2%

-28.8% vs TC avg

§112

14.3%

-25.7% vs TC avg

Black line = Tech Center average estimate • Based on career data from 898 resolved cases

Prosecution Timeline

Oct 17, 2023

Application Filed

Mar 27, 2026

Non-Final Rejection (current)

Precedent Cases

Applications granted by this same examiner with similar technology

16/868,691

Patent 12606796

DELIVERY OF ONCOLYTIC VIRUSES USING DENDRITIC CELLS

5y 11m to grant Granted Apr 21, 2026

16/977,320

Patent 12600946

METHOD FOR INCREASING DENDRITIC CELL MIGRATION ABILITY, AND USE THEREOF

5y 7m to grant Granted Apr 14, 2026

18/512,432

Patent 12600780

Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules that Bind CD3 and CD20, and Uses Thereof

2y 4m to grant Granted Apr 14, 2026

17/025,656

Patent 12577326

Recombinant Cell Surface Capture Proteins

5y 6m to grant Granted Mar 17, 2026

17/417,480

Patent 12577305

MULTISPECIFIC ANTIGEN BINDING PROTEINS CAPABLE OF BINDING CD19 AND CD3, AND USE THEREOF

4y 8m to grant Granted Mar 17, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

45%

Grant Probability

85%

With Interview (+40.5%)

3y 9m (~1y 2m remaining)

Median Time to Grant

Low

PTA Risk

Based on 898 resolved cases by this examiner. Grant probability derived from career allowance rate.